SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Threshold Pharmaceuticals, Inc. Reports Updated Phase 2 Results Including Analysis of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma